Nestic D, Custers J, Svec D, Majhen D
Microbiol Spectr. 2022; 10(4):e0109722.
PMID: 35924932
PMC: 9430667.
DOI: 10.1128/spectrum.01097-22.
Custers J, Kim D, Leyssen M, Gurwith M, Tomaka F, Robertson J
Vaccine. 2021; 39(22):3081-3101.
PMID: 33676782
PMC: 7532807.
DOI: 10.1016/j.vaccine.2020.09.018.
Ismail A, Zhou X, Dyer D, Seto D, Rajaiya J, Chodosh J
FEBS Lett. 2019; 593(24):3583-3608.
PMID: 31769017
PMC: 7185199.
DOI: 10.1002/1873-3468.13693.
Yu X, Veesler D, Campbell M, Barry M, Asturias F, Barry M
Sci Adv. 2017; 3(5):e1602670.
PMID: 28508067
PMC: 5425241.
DOI: 10.1126/sciadv.1602670.
Liu E, Wadford D, Seto J, Vu M, Hudson N, Thrasher L
PLoS One. 2012; 7(3):e33212.
PMID: 22427992
PMC: 3302849.
DOI: 10.1371/journal.pone.0033212.
Molecular evolution of human species D adenoviruses.
Robinson C, Seto D, Jones M, Dyer D, Chodosh J
Infect Genet Evol. 2011; 11(6):1208-17.
PMID: 21570490
PMC: 3139803.
DOI: 10.1016/j.meegid.2011.04.031.
Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28.
Kahl C, Bonnell J, Hiriyanna S, Fultz M, Nyberg-Hoffman C, Chen P
Vaccine. 2010; 28(35):5691-702.
PMID: 20600496
PMC: 2927224.
DOI: 10.1016/j.vaccine.2010.06.050.
Incidence of adenovirus infection: a family study.
Joncas J, Moisan A, AVILANIS V
Can Med Assoc J. 1962; 87:52-8.
PMID: 14452211
PMC: 1849417.
NEUTRALIZATION OF THE ADENOVIRUSES TYPES 1 TO 28: SPECIFICITY AND ANTIGENIC RELATIONSHIPS.
Wigand R, Bauer H, Lang F, Adam W
Arch Gesamte Virusforsch. 1965; 15:188-99.
PMID: 14269253
DOI: 10.1007/BF01257730.
[ON THE CYTOPATHOGENIC EFFECT OF ADENOVIRUSES IN MAN].
Wigand R, Bauer H
Arch Gesamte Virusforsch. 1964; 14:674-82.
PMID: 14247363
[PROPERTIES OF ADENOVIRUS HEMAGGLUTININS].
Bauer H, Wigand R
Z Hyg Infektionskr. 1963; 149:96-113.
PMID: 14047076
Viruses of diseases of the respiratory tract.
Stuart-Harris C
Br Med J. 1962; 2(5309):869-78.
PMID: 13917941
PMC: 1926106.
DOI: 10.1136/bmj.2.5309.869.
Acute respiratory diseases of viral etiology. II. Adenoviruses.
Bell J, Rowe W, Rosen L
Am J Public Health Nations Health. 1962; 52:902-7.
PMID: 13866814
PMC: 1523061.
DOI: 10.2105/ajph.52.6.902.
New human adenovirus (candidate adenovirus 36), a novel member of subgroup D.
Wigand R, Gelderblom H, Wadell G
Arch Virol. 1980; 64(3):225-33.
PMID: 7406681
DOI: 10.1007/BF01322702.
Immunological relationship among human adenoviruses of subgenus D.
Wigand R, Keller D, Werling I
Arch Virol. 1982; 72(3):199-209.
PMID: 6180704
DOI: 10.1007/BF01348965.
Serologically intermediate adenovirus strains: a regular feature of group II adenoviruses.
Wigand R, Fliedner D
Arch Gesamte Virusforsch. 1968; 24(3):245-56.
PMID: 5698889
DOI: 10.1007/BF01241296.
[Serologically intermediary adenovirus strains].
Wigand R
Arch Gesamte Virusforsch. 1965; 17(5):611-8.
PMID: 4956737
Comparison of immunization methods for producing reference adenovirus antisera in horses.
Hierholzer J, Gamble W, QUIST K, Chappell W
Appl Microbiol. 1972; 24(3):398-404.
PMID: 4562476
PMC: 376530.
DOI: 10.1128/am.24.3.398-404.1972.
Tumors induced in hamsters by a strain of adenovirus type 3: sharing of tumor antigens and "neoantigens" with those produced by adenovirus type 7 tumors.
HUEBNER R, Casey M, Chanock R, Schell K
Proc Natl Acad Sci U S A. 1965; 54(2):381-8.
PMID: 4285931
PMC: 219674.
DOI: 10.1073/pnas.54.2.381.
Reference equine antisera to 33 human adenovirus types: homologous and heterologous titers.
Hierholzer J, Gamble W, Dowdle W
J Clin Microbiol. 1975; 1(1):65-74.
PMID: 1236869
PMC: 274943.
DOI: 10.1128/jcm.1.1.65-74.1975.
